Related Experiment Video
Updated: Aug 17, 2026

Modified Technique for Coronary Artery Ligation in Mice
Published on: March 29, 2013
Effects of pharmacological myocardial depression on coronary artery collateral formation
Insights
Beta-blocker treatment for angina may hinder the development of new blood vessels (collateralization) in the heart. This experimental study in dogs suggests reduced collateral formation when oxygen demand is pharmacologically lowered.
Area of Science:
- Cardiology
- Pharmacology
- Experimental Medicine
Background:
- Angina pectoris treatment involves increasing blood flow or reducing oxygen demand.
- Beta-blockers reduce myocardial oxygen demand but may impede collateralization.
- The impact of beta-blockade on coronary collateral development requires investigation.
Purpose of the Study:
- To investigate the effect of propranolol (a beta-blocker) on experimentally induced coronary collateralization.
- To determine if reducing myocardial oxygen demand interferes with the formation of new blood vessels in the heart.
Main Methods:
- 25 dogs underwent ameroid constrictor placement to induce collateralization.
- Groups received immediate propranolol, delayed propranolol, or no propranolol treatment.
- Evaluations included surface mapping, angiographic collateral mapping, and hemodynamic studies.
Main Results:
- Acute propranolol treatment significantly depressed collateral formation.
- Hemodynamic evidence showed reduced coronary flow and altered pressures in treated dogs.
- Effects on established collaterals with delayed treatment were inconsistent.
Conclusions:
- Pharmacological reduction of myocardial oxygen demand experimentally reduces coronary collateralization.
- Beta-blocker use in multivessel coronary disease warrants further evaluation, especially compared to direct bypass.
- Findings suggest potential limitations of beta-blockers in promoting compensatory blood flow in certain coronary conditions.
Abstract:
Treatment of angina pectoris falls within two spheres: (1) increasing myocardial blood flow (direct bypass, vasodilators), or (2) reducing oxygen demand (beta blockade, propranolol). If the latter depresses the stimulus for collateralization without improving input, its use in certain forms of coronary disease may require reconsideration. To examine this hypothesis, 25 dogs (four groups) were evaluated by surface mapping, angiographic collateral mapping, and hemodynamic studies including cardiac output, systemic and coronary pressures, coronary flow, and left ventricular end-diastolic pressure, pressure to time (LVdp/dt). Collateralization was induced with ameroid constrictor placement in Groups I, III, and IV. Groups II and III received immediate propranolol treatment (3 to 5 mg. per kilogram per day for 6 weeks); Group IV received delayed treatment (4 weeks after constriction); and Group I received no propranolol (constrictor alone). Collateral formation was depressed significantly in the acutely beta-blockaded dogs (Group III) by surface and angiographic mapping and by hemodynamic evidence of depressed coronary flow and altered coronary retrograde pressures. Alterations in established collaterals (Group IV) were not consistent. These data suggest that pharmacological reduction of myocardial oxygen demand reduces coronary collateralization experimentally, requiring further evaluation of its usage in multivessel coronary disease to the exclusion of direct bypass.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Pathophysiology of Cardiac Performance
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis III: Medical Management